Slide 1: Fourth Quarter & Year Ended December 31, 2024 Investors Call
March 2025 Fourth Quarter & Year Ended December 31, 2024 Investors Call
Slide 2: Forward-Looking Statement
FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials
Slide 3: Kamada - A Global Biopharmaceutical Company
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15 % CAGR (from 2021) $ 178 - 182M 2025 Revenues Guidance $ 38 - 42M 2025 Adj. EBIDTA Guidance 4 Pillars of Growth A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF MA
Slide 4: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS 4
Slide 5: 2024 Continuing the Growth: Double Digit Revenue and Profitable Increase
GROSS MARGIN REVENUE 4bp 2023 39% 2024 43 % 13% 2023 $142.5 2024 $ 161.0 Adj. EBITDA EPS 42% 2023 $24.1 2024 $ 34.1 X1.7 2023 $0.15 2024 $0.25 2024 CONTINUING THE GROWTH DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE 5 For reconciliation of Adjusted EBITDA please refer to slide 17 Declares special cas
Slide 6: Annual Double-Digit Growth Trajectory
6 18 24 34 38 - 42 2021 2022 2023 2024 2025 104 129 142 161 178 - 182 2021 2022 2023 2024 2025 ADJUSTED EBITDA US$M 61% CAGR 2025 represents annual guidance 2025 represents annual guidance ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 15% CAGR 6 Cash Provided by Operating Activities of $47.6
Slide 7: Kamada's Roadmap for Continued Annual Double-Digit Growth
KAMADA ’ S ROADMAP FOR CONTINUED ANNUAL DOUBLE - DIGIT GROWTH 7 Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories ; and Distribution portfolio in Israel M&A Transactions Support growth through M&A transactions Plasma Collection Centers Each new center expected to contribute
Slide 8: FDA-Approved Specialty Plasma Products
8 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of
Slide 9: A Global Leader in Anti-Rabies Immune Globulin (HRIG)
$ 150 M Total U.S HRIG market size, KEDRAB presents double - digit growth YoY Only anti - Rabies IgG product with FDA approved label confirming safety and effectiveness in children KEDRAB /KAMRAB $ 50 M 2024 U.S. Revenues; $ 135 M Minimum sales in the U.S. expected in 2025 - 2027 Only 2 FDA approved
Slide 10: CYTOGAM CMV Immune Globulin
CYTOGAM is the only plasma - derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause for organ rejection post - transplant CYTOGAM ĎČĎď - 2024 Product re - launch, working with U.S. KOLs to generate new clinical and medic
Slide 11: Distribution Segment Growth
DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES Key areas : plasma - derived, respiratory, rare diseases, infectious dise
Slide 12: M&A Transactions
12 M&A TRANSACTIONS AIMING TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS DURING 2025 ; LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Exploring strategic business development opportunities to identify potential acquisition or in - licensing to accelerate long - term gr
Slide 13: Kamada Plasma: Expanding Vertical Integration & Revenue Growth
13 KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Recently opened a new plasma collection center in Houston, Texas ; planning to open another center in San Antonio,
Slide 14: Inhaled AAT Phase 3 Pivotal Study
$ 2 Billion A substantial market opportunity ( 2028 ) č Based on expected changes to the statistical analysis plan, intend to reduce the study sample size to approximately 180 patients , and conduct an interim futility analysis by the end of 2025 FDA recently reconfirmed overall study design, endors
Slide 15: Inhaled AAT Phase 3 Pivotal Study
INHALED AAT PHASE 3 PIVOTAL STUDY Non - Invasive, at - home treatment. Expected better ease of use and quality of life for AATD patients than current IV SOC Most effective mode of treatment for delivering therapeutic quantities of AAT directly into the airways Studied in more than 200 individuals to
Slide 16: Q4 and FY 2024 Financial Details
16 DETAILS Q4/23 Q4/24 FY 2023 FY 2024 US $ M Driven by two key growth drivers, KEDRAB® & CYTOGAM® 29.0 31.4 115.4 141.5 PROPRIETARY 7.4 7.6 27.1 19.5 DISTRIBUTION 13% YoY increase; over mid - point annual guidance 36.4 39.0 142.5 161.0 TOTAL REVENUES 14.4 17.0 55.5 70.0 GROSS PROFIT 4 basis point i
Slide 17: Non-IFRS Measures – Adjusted EBITDA
17 NON - IFRS MEASURES – ADJUSTED EBITDA Q4/23 Q4/24 FY 2023 FY 2024 US $ M 5.1 3.8 8.3 14.5 NET PROFIT (0.0) (1.3) 0.1 (1.1) TAXES ON INCOME (2.4) 2.8 1.0 8.1 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION 0.1 (0.1) 0.7 (1.4) OTHER FINANCIAL EXPENSE, NET 1.8 1.8 7.1 7.1 AMORTIZATION OF
Slide 18: Kamada - A Global Biopharmaceutical Company: Delivering on Our Commitments
KEDRAB® CYTOGAM® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15 % CAGR (from 2021) $ 178 - 182M 2025 Revenues Guidance $ 38 - 42M 2025 Adj. EBIDTA Guidance 4 Pillars of Growth DELIVERING ON OUR COMMITMENTS 18 Organic Growth M&A Transactio
Slide 19: Thank You
THANK YOU www.kamada.com